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Abstract
B-cell lymphoma-2 (Bcl-2) is an antiapoptotic protein known to be important in the regulation of apoptosis in various cell
types. However, its role in malignant transformation and tumorigenesis of human lung cells is not well understood. We
previously reported that chronic exposure of human lung epithelial cells to the carcinogenic hexavalent chromium Cr(VI)
caused malignant transformation and Bcl-2 upregulation; however, the role of Bcl-2 in the transformation is unclear. Using
a gene silencing approach, we showed that Bcl-2 plays an important role in the malignant properties of Cr(VI)-transformed
cells. Downregulation of Bcl-2 inhibited the invasive and proliferative properties of the cells as well as their colony forming
and angiogenic activities, which are upregulated in the transformed cells as compared to control cells. Furthermore, animal
studies showed the inhibitory effect of Bcl-2 knockdown on the tumorigenesis of Cr(VI)-transformed cells. The role of Bcl-2
in malignant transformation and tumorigenesis was confirmed by gene silencing experiments using human lung carcinoma
NCI-H460 cells. These cells exhibited aggressive malignant phenotypes similar to those of Cr(VI)-transformed cells.
Knockdown of Bcl-2 in the H460 cells inhibited malignant and tumorigenic properties of the cells, indicating the general role
of Bcl-2 in human lung tumorigenesis. Ingenuity Pathways Analysis (IPA) revealed potential effectors of Bcl-2 in
tumorigenesis regulation. Additionally, using IPA together with ectopic expression of p53, we show p53 as an upstream
regulator of Bcl-2 in Cr(VI)-transformed cells. Together, our results indicate the novel and multifunctional role of Bcl-2 in
malignant transformation and tumorigenesis of human lung epithelial cells chronically exposed to Cr(VI).
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Introduction
Lung cancer is the leading cause of cancer mortality worldwide.
While the etiology of lung cancer caused by various agents
including cigarette smoke, air pollution, and heavy metals has
been established [1,2], the underlying mechanisms of tumorigen-
esis are not well understood. Current research indicates that long-
term exposure to inhaled carcinogens has the greatest impact on
the risk of lung cancer. Cr(VI)-containing compounds are
ubiquitous carcinogens associated with the incidence of lung
cancer in humans. Several epidemiological studies in the last few
decades have associated exposure to Cr(VI) with the induction of
lung cancer in workers in various occupational settings [3–6].
Cr(VI) compounds are also present in cigarette smoke, automobile
emissions, and are widespread in the environment, e.g., Cr(VI)-
contaminated water [7,8]. In the United States, an air quality
survey indicated that people in several residential areas are
exposed to particulate airborne chromium at concentrations
exceeding 100 times the chronic toxicity benchmark, which set
at 0.016 mg/m3 from the critical study used as the basis for
Environmental Protection Agency’s reference concentration for
Cr(VI) particulates [9,10]. Therefore, in addition to occupational
exposure, environmental chromium at high concentrations is an
emerging concern for its associated long-term carcinogenic effect
on the lungs.
Cr(VI)-containing compounds have been designated as Class I
human carcinogens by IARC based on epidemiological data and
a large body of knowledge showing that they are mutagenic and
genotoxic [11]. However, animal studies have yielded inconsistent
or negative results [12–14] due to genetic variations or other
predisposing factors that are not well understood. The lack of good
animal models has hindered the efforts to identify the mechanisms
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of Cr(VI)-induced tumorigenesis. Therefore, even though Cr(VI)
compounds have been identified as human carcinogens, the
underlying mechanisms remain elusive. To date, most Cr(VI)
tumorigenesis studies have focused on short-term or acute
exposure effects; however, tumorigenesis is a long-term process
requiring chronic exposure to carcinogens. To mimic the
pathological process, we utilized a chronic exposure model of
human lung epithelial BEAS-2B cells and examined the long-term
effects of Cr(VI) exposure and the role of Bcl-2 in the cell
transformation and carcinogenic process. The BEAS-2B cells were
used because they exhibit similar characteristics and cellular
responses to carcinogen as the primary or normal lung cells. They
are also non-tumorigenic and can be grown continuously in the
culture, thus allowing long-term exposure studies.
Bcl-2 is an anti-apoptotic protein known to be important in the
regulation of apoptosis induced by various agents including Cr(VI)
[15,16]. We have previously shown that chronic exposure of lung
epithelial cells to Cr(VI) causes an upregulation of Bcl-2 [17].
However, its role in malignant transformation and tumorigenesis is
unknown. Several human small and non-small lung cancer cell
lines and tumor specimens have been shown to overexpress Bcl-2
[18–20]. This protein has also been shown to be upregulated in
many forms of cancer, including 90% of colorectal cancer, 70% of
breast cancer, and 30–60% of prostate cancer [21,22]. Accord-
ingly, anti-Bcl-2 strategies have been widely developed as novel
cancer therapy for various malignancies [21–23]. While these
studies suggest the potential role of Bcl-2 in Cr(VI)-induced
tumorigenesis, direct evidence is lacking. In this study, we used
a gene silencing approach to knockdown Bcl-2 in Cr(VI)-
transformed cells and studied its effects on cancer-associated
properties including cell growth, apoptosis, invasion, colony
formation, and angiogenesis. We also studied the tumorigenic
effect of Cr(VI)-transformed cells in vivo and examined the role of
Bcl-2.
Materials and Methods
Ethics statement
All animal procedures were conducted in accordance with the
guidelines for the Use and Care of Laboratory Animals and
approved by the West Virginia University Institutional Animal
Care and Use Committee (WVU IACUC).
Cell culture and reagents
Human lung epithelial BEAS-2B, human non-small (large) cell
lung cancer H460 cells derived from patient pleural effusion, and
human umbilical vein endothelial cells (HUVEC) were obtained
from American Type Culture Collection (ATCC; Manassas, VA).
BEAS-2B cells were cultured in DMEM medium containing 5%
fetal bovine serum (FBS), 2 mM L-glutamine, 100 units/ml
penicillin/streptomycin. H460 cells were cultured in RPMI 1640
medium containing 10% FBS. HUVEC cells were cultured in
F12K medium supplemented with 10% FBS, 0.1 mg/ml heparin
sulfate, 0.05 mg/ml endothelial cell growth factor supplement (BD
Biosciences, San Jose, CA), 100 units/ml penicillin/streptomycin.
All cells were cultured in a 5% CO2 environment at 37uC. Sodium
dichromate (Na2Cr2O7.2H2O) [Cr(VI)] was obtained from Sigma
(St. Louis, MO). Lipofectamine was obtained from InVitrogen
(Carlsbad, CA). Hoechst 33342 was from Molecular Probes
(Eugene, OR).
Chronic Cr(VI) exposure
Subconfluent cultures of BEAS-2B cells (16105 cells) in 6-well
plates were continuously exposed to 5 mM Cr(VI). Cr(VI)-
containing culture medium was changed every 3 to 4 days and
the cells were passaged weekly at preconfluent (,80%) densities.
The Cr(VI)-treated cells are designated as BEAS-Cr cells so as to
distinguish them from the parental BEAS-2B cells. Parallel
cultures grown in Cr(VI)-free medium provided passage-matched
Figure 1. Bcl-2 expression and effect of Bcl-2 knockdown on cell growth. (A) Endogenous Bcl-2 levels in BEAS-2B, BEAS-Cr and H460 cells
determined by Western blot analysis. Densitometry was performed to determine the relative Bcl-2 levels after reprobing the membrane with b-actin
antibody. (B) Bcl-2 knockdown experiments were performed in BEAS-Cr and H460 cells by infecting the cells with Bcl-2 shRNA (shBcl-2) viral particles
or control shRNA (shCon) particles as described under Materials and Methods. Clonal selection and Bcl-2 expression were performed to identify
mutants with downregulated Bcl-2. (C) BEAS-2B, BEAS-Cr and H460 cells (16105 cells) were seeded on 60-mm cell culture dishes and were incubated
at 37uC in a 5% CO2 incubator. At the indicated times, cells were trypsinized and analyzed for cell number using an electronic cell counter. (D) Effect
of Bcl-2 on cell growth of the respective cell lines and their mutants. Cells (16105 cells) were seeded and incubated at 37uC for 96 h, after which they
were analyzed for cell number. Values are means (6 SD) (n=4). *P,0.05 versus passage-control BEAS-2B cells. # P,0.05 versus the respective BEAS-
Cr and H460 cells.
doi:10.1371/journal.pone.0037045.g001
Bcl-2-Induced Tumorigenesis
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controls. After 24 weeks of exposure, Cr(VI)-treated cells were
cultured in normal medium and their malignant transformation
and tumorigenic properties were assessed as described below.
Cell growth assay
Cells (16105 cells) were seeded on 60-mm cell culture dishes. At
specific times after the incubation, cells were trypsinized and
analyzed for cell number using a CountessH automated cell
counter (InVitrogen, Carlsbad, CA).
Soft agar colony formation assay
Soft agar assay was performed as previously described with
minor modifications [24]. The cell lines studied (36104 cells) were
mixed with tissue culture medium containing 0.5% agar to result
in a final agar concentration of 0.33%. The cell suspension
(1.5 ml) was plated into 60-mm dishes coated with 7 ml of 0.5%
agar into culture medium. After 2 weeks, the average number of
colonies with a size of more than 50 cells was scored under a light
microscope.
Migration and invasion assays
Cell migration was determined by wound assay as detailed
previously [25]. Briefly, monolayer of cells was cultured in 24-well
plate, and a wound space was made with 1 mm width tip. After
rinsing with PBS, the cell monolayers were allowed to migrate for
24 h. Cell migration was measured by light microscopy and
quantified by calculating the percentage of change in the wound
space as previously described [25]. Relative cell migration was
calculated by dividing the percentage change in the wound space
of transformed cells by that of the control cells in each experiment.
Invasion assays were performed using TranswellH chambers
coated with MatrigelH (50 ml per filter) (BD Biosciences, NJ)
according to the manufacturer’s protocol. Medium containing 5%
FBS was used as a chemo-attractant. After 24 h incubation, cells
that invaded to the underside of chamber were stained with
Hoechst 33342.
Angiogenesis tube formation assay
Growth factor-reduced MatrigelH was placed in 24-well plates
(150 ml/well) and allowed to set at 37uC for 30 min. HUVEC cells
(46104cells) suspended in 2.5% dialyzed FBS medium were
incubated with cell-primed supernatants from epithelial cells
(0.56106 cells/6-well plate) at the ratio of 1 to 1, and added to
the MatrigelH-coated plates. Tube formation of HUVEC cells was
observed and photographed using a phase contrast microscope
after 24 h. The number of nodes formed was scored from at least
five different fields for each well.
Apoptosis assay
Apoptosis was determined by Hoechst 33342 DNA fragmen-
tation assay. Briefly, cells were incubated with 10 mg/ml of
Hoechst 33342 for 30 min and analyzed for apoptosis by scoring
the percentage of cells having intensely condensed chromatin and/
or fragmented nuclei by fluorescence microscopy (Leica Micro-
systems, Bannockburn, IL). Approximately 1,000 nuclei from ten
random fields were analyzed for each sample. The apoptotic index
was calculated as the percentage of cells with apoptotic nuclei over
total number of cells.
Generation of Bcl-2 knockdown clones
Lentiviral transduction particles carrying short hairpin RNA
(shRNA) sequence against human Bcl-2 (59-CCGGGTGAT-
GAAGTACATCCATTATCTCGAGATAATGGATGTACTT-
CATCA CTTTTG-39) and control non-target sequence (59-
CCGGCAACAAGATGAAGAGCACCAACT
CGAGTTGGTGCTCTTCATCTTGTTGTTTTT-39) were
used to downregulate Bcl-2 expression in BEAS-Cr and H460
cells. The viral vectors were obtained from Sigma (Cat# SHVRS-
Figure 2. Effect of Bcl-2 knockdown on colony formation of BEAS-Cr and H460 cells. (A) BEAS-2B, BEAS-Cr and H460 cells (36104 cells)
were seeded on 0.5% agar plates and incubated at 37uC in a 5% CO2 incubator. After 2 weeks, colony formation capacity of the cells was scored
under a light microscope. (B) Effect of Bcl-2 on colony formation capacity of the respective cell lines and their mutants. Cells (36104 cells) were
seeded on soft agar plates and the colonies were scored after 2 weeks. (C) Representative micrographs of colonies formed by the cell lines and
mutants on soft agar are shown. Values are means (6 SD) (n= 4). *P,0.05 versus passage-control BEAS-2B cells. #P,0.05 versus the respective BEAS-
Cr and H460 cells.
doi:10.1371/journal.pone.0037045.g002
Bcl-2-Induced Tumorigenesis
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NM_000633 and SHC002V, respectively) and were used accord-
ing to the manufacturer’s protocol at the multiplicity of infection of
1.5. For generation of stable clones, cells were cultured for 14 days
with puromycin at 1 mg/ml concentration. Resistant clones
expressing varying levels of Bcl-2 were isolated using cloning
cylinders (Bellco Glass, Vineland, NJ) and transferred for
expansion and analysis by Western blotting.
Western blotting
Preparation of cell lysates and Western blotting were performed
as described previously [16]. We obtained antibodies for Bcl-2, b-
actin, and peroxidase-conjugated secondary antibodies from Santa
Cruz Biotechnology (Santa Cruz, CA). The immune complexes
were detected by chemiluminescence and quantified using
analyst/PC densitometry software (Bio-Rad Laboratories, Hercu-
les, CA).
In vivo tumorigenesis
Male athymic (nu/nu) nude mice obtained from Jackson
Laboratory (Bar Harbor, ME) were housed under pathogen-free
conditions and fed an autoclaved diet and water ad libitum. To
establish tumor xenografts in mice, BEAS-2B, BEAS-Cr, H460
and Bcl-2 knockdown cells (16106 cells) were suspended in 1:1
medium mixed with MatrigelH and were injected subcutaneously
on the left and right flanks of each mouse. Tumor size was
measured at 14 days post-injection by using a caliper, and the
tumor volume was determined using the formula: 0.52386L
(length)6W (width)6H (height) of the tumor. All procedures were
conducted in accordance with the guidelines for the Use and Care
of Laboratory Animals and approved by the West Virginia
University Institutional Animal Care and Use Committee (WVU
IACUC).
Bcl-2-interactome analysis
The Ingenuity Pathways Analysis (IPA) software (Ingenuity
Systems, Redwood City, CA) was used to analyze the currently
published Bcl-2 interactome. The Ingenuity database is the largest
curated database of previously published findings on mammalian
biology from the public literature (i.e., MEDLINE). Reports on
individual studies of genes in human, mouse or rat were first
identified from peer-reviewed publications, and findings were then
encoded into ontology by content and modeling experts. Network
analysis using the knowledge base was used to further identify
direct interactions between mammalian orthologues. The Bcl-2-
interactome is a graphical representation of its published
molecular relationships. Molecules are represented as nodes, and
Figure 3. Effect of Bcl-2 knockdown on cell invasion and migration of BEAS-Cr and H460 cells. (A) BEAS-2B, BEAS-Cr and H460 cells
(16105 cells) were added to TranswellH inserts coated with MatrigelH and incubated for 24 h. Invading cells were stained and counted under a light
microscope. Plots show relative invasion of BEAS-2B, BEAS-Cr and H460 cells. (B) Effect of Bcl-2 on cell invasion of the respective cell lines and their
mutants. Experiments were repeated with the indicated cell lines and analyzed for cell invasion. (C) Confluent monolayers of BEAS-2B, BEAS-Cr and
H460 cells were wounded, and the cells were allowed to migrate for 24 h. Wound space was visualized by light microscopy and analyzed by
comparing the relative change in wound space as compared to control cell monolayers. (D) Effect of Bcl-2 on cell migration of the respective cell lines
and their mutants. Cells were wounded and analyzed for cell migration over a 24 h period. (E) Representative micrographs of cells stained for invasion
are shown. Values are means (6 SD) (n= 4). *P,0.05 versus passage-control BEAS-2B cells. #P,0.05 versus the respective BEAS-Cr and H460 cells.
doi:10.1371/journal.pone.0037045.g003
Bcl-2-Induced Tumorigenesis
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the biological relationship between two nodes is represented as an
edge (line). Nodes are displayed using various shapes that represent
the functional class of the gene product. Edges are displayed with
various labels that describe the nature of the relationship between
the nodes.
Statistical analysis
The data were expressed as means 6 SD of three or more
independent experiments. Statistical analysis was performed using
two-tailed and paired Student’s t-test. P values less than 0.05 were
considered statistically significant and indicated by an asterisk.
Results
Bcl-2 expression and cell growth
Abnormal cell growth is a key characteristic of cancer cells. We
determined the growth characteristic of Cr(VI)-transformed cells
(BEAS-Cr) generated by chronically exposing non-carcinogenic
BEAS-2B cells to Cr(VI) over 24 weeks as described under
Materials and Methods. To determine the role of Bcl-2 in the process,
the transformed BEAS-Cr cells were first analyzed for Bcl-2
expression and cell growth characteristics. Passage-matched
BEAS-2B cells and human lung cancer H460 cells were used as
a negative and positive control, respectively. Figure 1A shows that
BEAS-Cr cells exhibited a higher level of Bcl-2 protein expression
as compared to passage-control BEAS-2B cells, but comparable to
H460 cells. To study the role of Bcl-2 in Cr(VI)-induced
transformation, mutant cell lines exhibiting stably downregulated
Bcl-2 were generated from BEAS-Cr and H460 cells using RNA
interference and clonal selection. Figure 2B shows that maximum
Bcl-2 downregulation in BEAS-Cr mutants (85%) was achieved in
clone 2, whereas maximum reduction in H460 mutants (75%) was
obtained in clone 1, which were used in subsequent studies.
Figure 1C shows that as compared to control BEAS-2B cells,
BEAS-Cr and H460 cells exhibited a significantly higher growth
rate which was observed as early as 48 h post-seeding. By 96 h, the
growth rates of BEAS-Cr and H460 cells were more than double
that of the control BEAS-2B cells. Knockdown of Bcl-2 in BEAS-
Cr and H460 cells reduced the growth rates by about 50% at 96 h
(Figure 1D).
Colony formation
Soft agar colony formation assays were performed to assess the
relative colony forming activities of the cells. BEAS-2B, BEAS-Cr,
and H460 cells were subjected to colony formation assay by
growing them on agar plates so as to assess anchorage-
independent growth. After 2 weeks, significant colony formation
was observed in BEAS-Cr cells with a 7-fold increase as compared
to passage-control BEAS-2B cells which also formed very few, slow
growing colonies (Figure 2A and C). The H460 lung cancer cells
exhibited the highest colony formation capacity, out-growing the
BEAS-2B cells by approximately 8-fold and BEAS-Cr cells by
approximately 1.5-fold. Next, the effect of Bcl-2 knockdown on
colony formation capacity was evaluated. The BEAS-Cr mutant
exhibited approximately 60% reduction in colony formation,
while a 40% reduction was observed in the H460 mutant as
compared to their respective controls (Figure 2B and C).
Invasion and migration
We next investigated the relative aggressive-malignant pheno-
types of the cells using the TranswellH invasion and wound
migration assays. The H460 cells showed the highest invasion
Figure 4. Effect of Bcl-2 knockdown on angiogenic activity of BEAS-Cr and H460 cells. (A) BEAS-2B, BEAS-Cr, and H460 cell supernatants
were incubated with HUVEC cells, and endothelial capillary tube formation was detected under a light microscope. The number of nodes formed by
the tubes were scored and plotted. (B) Effect of Bcl-2 knockdown on angiogenic activity of the respective cell lines. Experiments were performed with
the indicated cell lines and analyzed for endothelial tube formation as described. (C) Representative micrographs of tube formation are shown.
Values are means (6 SD) (n= 4). *P,0.05 versus passage-control BEAS-2B cells. #P,0.05 versus the respective BEAS-Cr and H460 cell supernatants.
doi:10.1371/journal.pone.0037045.g004
Bcl-2-Induced Tumorigenesis
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capacity with BEAS-Cr cells invading at the rate of 70% relative to
H460, and BEAS-2B invading at 15% (Figure 3A and E). A 7-fold
increase in invasion rate was observed in BEAS-Cr as compared to
BEAS-2B cells. The highest migration capacity was observed in
H460 cells followed by BEAS-Cr cells, at approximately 75% of
H460 cells, and finally, BEAS-2B cells, at less than 10% of H460
cells (Figure 3C). Knockdown of Bcl-2 in BEAS-Cr and H460 cells
substantially reduced their invasion and migration capacities as
compared to controls (Figure 3B, D and E).
Angiogenesis
Angiogenesis is an essential step in tumor growth. We de-
termined whether Cr(VI)-transformed cells possess an angiogenic
activity and whether Bcl-2 regulates this activity by performing
vascular endothelial tube formation assay. HUVEC cells were
incubated with cell-primed supernatants from BEAS-Cr, H460, or
control BEAS-2B cells in MatrigelH-coated plates, and analyzed
for endothelial capillary tube formation. Figure 4A and C shows
that BEAS-Cr and H460 cell supernatants induced a higher
number of branch nodes and a more complex pattern of
endothelial tube formation as compared to control BEAS-2B cell
supernatants. This result indicates an increase in pro-angiogenic
activity of Cr(VI)-transformed cells which may be important in
Cr(VI)-induced tumorigenesis that has not been reported. Down-
regulation of Bcl-2 in BEAS-Cr and H460 cells inhibited their
angiogenic activity as compared to controls (Figure 4B and C).
This finding indicates a novel and positive regulatory role of Bcl-2
in angiogenesis.
Apoptosis resistance
Resistance to apoptosis is a foundation of neoplastic evolution
and a key characteristic of cancer cells. We tested whether Cr(VI)-
transformed cells exhibited apoptosis-resistant phenotype and
whether Bcl-2 plays a role. BEAS-Cr, H460, or control BEAS-2B
cells were treated with Cr(VI) and analyzed for apoptosis.
Figure 5A shows that Cr(VI) treatment markedly induced
apoptosis of control BEAS-2B cells, whereas it had substantially
lesser effect in BEAS-Cr and H460 cells. Knockdown of Bcl-2 in
BEAS-Cr and H460 cells reversed their apoptosis resistance as
compared to their respective controls (Figure 5B and C). The
mechanistic similarity between BEAS-Cr and H460 cells suggests
that Bcl-2 is a general feature of apoptosis resistance to Cr(VI).
Effect of Bcl-2 knockdown on tumor formation in vivo
To assess the potential tumorigenicity of Cr(VI)-transformed
cells and the role of Bcl-2 in the process, experiments were
performed using a xenograft mouse model. BEAS-Cr and H460
cells and their Bcl-2 knockdown mutants were subcutaneously
injected into nude mice. At one week after the injection, small
tumors were formed at the injection site in mice receiving BEAS-
Cr and H460 cells, whereas mice receiving passage-control BEAS-
2B cells did not develop tumors. At 14 days post-injection, large
tumors were found in the BEAS-Cr (Figure 6A) and H460
(Figure 6B) mice, whereas no or very small lumps were observed in
the BEAS-2B control mice. Mice receiving Bcl-2 knockdown
mutants, either BEAS-Cr or H460, showed a substantial reduction
in tumor volume as compared to their respective controls
(Figure 6A and B). These results indicate the role of Bcl-2 in
tumorigenesis of Cr(VI)-transformed cells. The inhibition of tumor
growth in H460 mutant mice also implicates the general role of
Bcl-2 in the tumorigenesis of lung cancer cells.
Bcl-2-interactome analysis
In order to establish a strategy towards a better understanding
of the mechanism(s) involved in Bcl-2’s contribution to tumori-
genesis, we performed an extensive PubMed database search for
possible molecular targets. The initial query for Bcl-2 returned
33,970 hits! We realized that other approaches may need to be
evaluated given the complexity of Bcl-2 cellular role(s). Following
the analysis of available options, we turned to Ingenuity Pathways
Analysis (IPA). IPA integrates the primary literature into easily
searched and visualized networks allowing for orders of magnitude
faster evaluation of cellular signaling cascades. The initial IPA
query of Bcl-2’s interactions (IPA v8.6) returned 741 hits. In order
to make the network more relevant to our model, we filtered for
only those interactions reported in humans (Figure 7). This
reduced the interaction network to 56 molecules organized by
cellular localization (Bcl-2-interactome). Given that we selectively
targeted Bcl-2 and observed significant consequences on tumor-
associated properties, we asked IPA to map only the downstream
components of human Bcl-2-interactome known to date (Figure 8).
Figure 5. Apoptosis response to Cr(VI) treatment in BEAS-2B,
BEAS-Cr, and H460 cells. (A) BEAS-2B, BEAS-Cr and H460 cells were
treated with or without Cr(VI) (20 mM) for 12 h and apoptosis was
determined by Hoechst 33342 assay. (B) and (C) Effect of Bcl-2
knockdown on Cr(VI)-induced apoptosis of the respective cell lines
and their mutants. Values are means (6 SD) (n= 4). *P,0.05 versus non-
treated control. #P,0.05 versus Cr(VI)-treated passage-control BEAS-2B
cells. **P,0.05 versus Cr(VI)-treated respective BEAS-Cr and H460 cells.
doi:10.1371/journal.pone.0037045.g005
Bcl-2-Induced Tumorigenesis
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The query returned 20 molecules. As we progressed from the
initial overwhelming complexity of data to the more manageable
and relevant Figure 6B, the current mechanistic evidence of Bcl-
2’s role in tumorigenesis emerged, as did a new approach to
scientific query.
Regulation of Bcl-2 by p53
It is likely that multiple genes and signaling pathways are
involved in the different effects of Bcl-2. In an effort to understand
the mechanism of Bcl-2 regulation in Cr(VI)-transformed cells, we
investigated the potential role of p53 since it is known to regulate
several proteins in the Bcl-2 family [26] and it is shown by IPA
a direct upstream regulator of Bcl-2 (Figure 8). Cells were treated
with or without Cr(VI) and analyzed for Bcl-2 and p53 protein
levels by Western blotting. In non-treated cells, Bcl-2 expression
was substantially lower in the BEAS-2B cells as compared to
BEAS-Cr and H460 cells, whereas p53 expression was higher in
BEAS-2B cells (Figure 9A). The inverse relationship between Bcl-2
and p53 was also observed in Cr(VI) treated cells across the cell
lines tested, indicating the potential negative regulation of Bcl-2 by
p53. To test the direct role of p53 in Bcl-2 regulation in Cr(VI)-
transformed cells, BEAS-Cr cells were ectopically transfected with
p53, and Bcl-2 expression was evaluated by Western blotting.
Figure 9B shows that as compared to vector-transfected control,
the p53-transfected cells exhibited a substantially lower Bcl-2
expression, indicating p53 as a negative regulator of Bcl-2 in the
cell system.
Discussion
Although Cr(VI) compounds have been identified as human
carcinogens, the underlying mechanisms of tumorigenesis remain
unclear. In this study, we reported a combined in vitro-in vivo model
for Cr(VI) tumorigenesis studies using chronically exposed human
bronchial epithelial BEAS-2B cells and a mouse xenograft model.
Bronchial epithelial cells were chosen in this study because they
are a key target for Cr(VI)-induced tumorigenesis. BEAS-2B cells
have been widely used in the literature to define conditions under
which various agents and oncogenes cause neoplastic trans-
formation [27–29]. They have been shown to exhibit similar
characteristics and cellular responses to carcinogens as primary or
normal lung cells [30–32]. Although BEAS-2B cells have a mutated
p53Ser47 gene, previous studies have shown that this mutation does
not affect its growth suppressing and apoptotic function, which is
controlled by p53Ser15 and is normal in the BEAS-2B cells
[30,31,33]. Inclusion of the passage-control BEAS-2B cells and
bronchial carcinoma H460 cells into direct comparisons was
Figure 6. Effect of Bcl-2 knockdown on tumor-associated properties in vivo. (A) Mice were injected subcutaneously with 16106 passage-
control BEAS-2B, BEAS-Cr, or shBcl-2 BEAS-Cr cells. Tumor formation was determined at 14 d post-injection. Representative photographs are shown.
(B) Mice were similarly injected with control BEAS-2B, H460, or shBcl-2 H460 cells. Tumor formation and representative micrographs at 14 d post-
injection are shown. Data are means (6 SD) (n=4). *P,0.05 versus passage-control BEAS-2B cells. #P,0.05 versus the respective BEAS-Cr and H460
cells.
doi:10.1371/journal.pone.0037045.g006
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critical when assessing the significance of tumorigenic properties in
the evolved BEAS-Cr phenotype. H460 cells are a well established
model for in vitro and in vivo mechanistic studies of lung
tumorigenesis and therefore represent a positive control. For
BEAS-Cr cells, a significant growth increase was observed as early
as 48 h and at 96 h the growth rate was double that of control
BEAS-2B cells (Figure 1C). H460 cells proliferated even faster, at
approximately 2.5 times that of BEAS-2B cells.
Anchorage-dependent growth is a typical feature of normal cells
and controls cell division [34,35], however when cells are
transformed they lose this property. Anchorage-independent
growth has been widely correlated with the tumorigenicity and
invasiveness of several cancer cell types [36]. Soft agar assay is
a stringent test to study the ability of cells to undergo anchorage-
independent growth. The number of colonies formed by BEAS-Cr
cells was about 7 times more than that in control BEAS-2B cells,
confirming the carcinogenic potential of Cr(VI)-transformed cells
(Figure 2A and C). H460 cells formed colonies at even higher rate,
exceeding BEAS-Cr cells by about 30%. Interestingly, bronchial
epithelial BEAS-2B cells obtained at autopsy of non-cancerous
individuals also formed a small number of slow growing colonies
on soft agar, consistent with previous reports [28,35]. Additionally,
the American Type Culture Collection indicates that the BEAS-2B
cell line forms colonies in semisolid medium but is non-
tumorigenic in immunosuppressed mice. Therefore, the colony
formation observed in BEAS-2B cells is due to the indigenous
properties of the cell and not because of their tumorigenic
property.
Various carcinogenic properties representing the hallmarks of
cancer were further assessed in this study [36]. Cr(VI)-transformed
cells were first characterized for their invasive and migratory
properties and compared to those of established lung cancer H460
cells. Invasion and migration were shown to increase significantly
as compared to passage-control BEAS-2B cells (Figure 3A and C).
Previous studies indicate that BEAS-2B are non-tumorigenic,
aneuploid cells but can undergo squamous differentiation in
response to serum and transforming growth factor-b [37].
However, since passage-control BEAS-2B cells showed no
Figure 7. Ingenuity Pathways Analysis software output for the Bcl-2-interactome. IPA query for the Bcl-2-interactome. The interactome
was filtered for interactions reported in humans only and presented by cellular localization. 56 molecules were reported to interact either directly
(solid lines) or indirectly (dash lines). Arrow direction indicates direction of functionality.
doi:10.1371/journal.pone.0037045.g007
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phenotypic changes or malignant behavior, it can be concluded
that BEAS-Cr cells are Cr(VI)-transformed BEAS-2B cells and not
BEAS-2B cells that have undergone differentiation and show
altered phenotype due to continued passaging. The observation of
malignant transformation induced by long-term Cr(VI) exposure is
consistent with previous reports [38,39]. In addition, the results of
this study indicate that long-term exposure to Cr(VI) also
increased the proangiogenic activity of human lung epithelial cells
(Figure 4A and C). Since angiogenesis is required for tumor
growth, this new finding supports the in vivo tumorigenicity of
Cr(VI)-transformed cells shown in Figure 6A.
Bcl-2 is known to be a key anti-apoptotic protein involved in the
regulation of apoptosis [15,16]. In the present study, we
demonstrated that Bcl-2 dysregulation mediated BEAS-Cr and
H460 cells to acquire apoptosis resistance to Cr(VI) (Figure 5A–D).
We also found that p53 is a likely upstream regulator of Bcl-2 in
this cell system since its ectopic expression downregulated the Bcl-
2 level (Figure 9B). This result is good agreement with previous
reports showing the repression of Bcl-2 gene expression by p53
[40–42] and with Ingenuity Pathways Analysis showing p53 (TP53
gene) as an upstream regulator of Bcl-2 (Figure 8). The mechanism
by which p53 regulates Bcl-2 is incompletely understood, but is
believed to involve transcriptional regulation since the gene
promotor of Bcl-2 contains a p53-negative response element [42].
While the role of Bcl-2 in apoptosis regulation is well
established, its role in tumorigenesis is unclear. To determine this
relationship, gene knockdown experiments were performed to
assess the Bcl-2’s contribution to tumorigenic phenotype of BEAS-
Cr and H460 cells. Our results showed that Bcl-2 knockdown led
to a significant reduction of all malignant properties evaluated
(Figures 1–4). Furthermore, our in vivo data showed that BEAS-Cr
cells formed tumors in nude mice and that Bcl-2 knockdown
substantially inhibited the tumor formation (Figure 6A). This
mechanistic feature was nearly identical in human lung cancer
H460 derived tumors (Figure 6B), indicating a potential shared
mechanism between laboratory Cr(VI)-induced tumorigenesis and
human lung cancer.
Figure 8. Ingenuity Pathways Analysis software output for the downstream components of human Bcl-2-interactome. Twenty
molecules of downstream components were reported to date and were labeled in orange, while upstream molecules were labeled in green.
doi:10.1371/journal.pone.0037045.g008
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Given that we were interested in the mechanisms involved Bcl-
2’s contribution to tumorigenesis, we performed an IPA with the
main focus on Ingenuity’s output of known downstream effectors
of Bcl-2-interactome (Figure 8). Did any of the molecules listed
have a link to regulation of tumor-associated properties such as
proliferation, transformation, migration, invasion and colony
formation? Analysis of Ingenuity Knowledge Base (IKB) strongly
suggests YES. Out of all downstream Bcl-2 effectors, nucleus-
localized constituents strongly argue that Bcl-2’s role in tumori-
genesis exceeds that of apoptosis regulation in line with our
observations. Cyclin-dependent kinases 1 and 2 (CDK1&2)
regulate cell cycle progression, cellular motility and proliferation
according to IKB summary of over 6,000 categorized literature
findings. Their role in tumorigenesis is well established. Next,
telomerase (TERT) is an established positive regulator of cell
proliferation, immortalization and transformation. Its role in
tumorigenesis is widely accepted. Of interest, RAD9A, implicated
in the regulation of colony formation also appears in the IPA’s
output. Relative to its ‘‘neighbors’’, it is a less studied protein with
only 380 categorized literature findings in the IKB. Lastly,
vascular endothelial growth factor (VEGF) is a well established
positive regulator of angiogenesis and is a downstream target of
Bcl-2. Inhibition of vascular endothelial tube formation by Bcl-2
knockdown of BEAS-Cr and H460 cells (Figure 4B and C)
supports the pro-angiogenic role of Bcl-2 which has not been
directly demonstrated.
In conclusion, evidence presented in this report supports the
role of Bcl-2 in Cr(VI)-induced lung tumorigenesis. Bcl-2 is
upregulated in Cr(VI)-transformed cells and contributes to the
apoptosis resistant phenotype of the cells. Such upregulation also
contributes to the malignant properties of the cells including their
invasiveness, angiogenicity, and anchorage-independent cell
growth. Furthermore, animal studies support its role in tumori-
genesis in vivo. Collectively, our data indicate the multifunctional
role of Bcl-2 in the regulation of cell transformation and
tumorigenesis in addition to its established role as an apoptosis
regulator.
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